SAUDI-FUND-DEVELOPMENT
2.9.2024 20:55:35 CEST | Business Wire | Press release
The Saudi Fund for Development (SFD) celebrated its 50th anniversary in Riyadh today, under the theme "50 Years of Global Impact." The event brought together key development partners to reflect on the SFD’s significant contributions to sustainable development worldwide. Over the past five decades, the SFD has allocated over $20 billion, financing more than 800 development projects and programs in vital sectors, including social infrastructure (education, healthcare, water and sewage, and housing and urban development), communication and transportation (roads, railways, airports and seaports), energy, agriculture, mining and industry, and others.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240902588222/en/
Saudi Fund for Development Celebrates 50 Years of Global Impact with Over $20 Billion in Development Contributions (Photo: AETOSWire)
Since its inception in 1974, the SFD has been the international development arm of the Kingdom of Saudi Arabia and has provided critical support to over 100 developing nations around the world. With a strong focus on supporting countries to achieve the Sustainable Development Goals (SDGs), the SFD has played a pivotal role in driving sustainable development in Least Developed Countries (LDCs) and Small Island Developing States (SIDS).
During the event, SFD Chairman H.E. Ahmed Al-Khateeb emphasized the importance of collaboration in driving global development. He highlighted that SFD's success is deeply rooted in its partnerships, with 27 development projects and programs in 23 developing countries in 2023 co-financed with other funders. He also underscored the need to forge new partnerships and strengthen existing ones to create a world where every individual has the opportunity to reach their full potential.
Reflecting on this significant milestone, the SFD CEO , Mr. Sultan bin Abdulrahman Al-Marshad, stated: “As we celebrate five decades of impactful work, we are committed, now more than ever, to supporting developing countries on their journey to economic self-reliance and resilience. Our goal is to ensure that all children can go to school, that education is not a privilege but something every child should have access to, and that families have access to healthcare and basic vital services. Equally, we focus on critical infrastructure development, like building roads and enhancing airports and sea ports, so that countries can thrive and engage in economic activities and trade. This work is not just about financing; it’s about tangibly improving lives, creating opportunities, empowering communities, and building a more prosperous future.”
On the sidelines of the 50th Anniversary Gala, the SFD and the Asian Development Bank (ADB) signed a new $25 million agreement to co-finance a renewable energy development project in the Solomon Islands. This marks the first project for SFD in the Solomon Islands. The primary aim of the project is to develop renewable energy infrastructure, reduce dependency on fossil fuels, and promote sustainable development in the region.
This agreement builds on SFD’50 years of transformative impact through development projects that have spanned Africa, Asia and the Pacific, Latin America and the Caribbean, and Eastern Europe.
This includes key projects such as the Metolong Dam in Lesotho, which received $25 million in funding and now provides potable water to 280,000 people, enhancing water security and public hygiene and health in the region. This is just one of the 433 projects across Africa, with a total funding of $11.5 billion, which focuses on critical areas such as infrastructure and water security.
In Asia, the SFD has funded 271 projects with a total funding of $7.8 billion. One notable example is the SFD’s contribution to the Mohmand Dam Hydropower Project in Pakistan, which has an overall project cost of $240 million. The projects contributes to the country’s energy security and flood resilience by generating 800 megawatts of renewable energy and storing 1.6 million cubic meters of water.
In Latin America and the Caribbean, the SFD has financed 21 projects, totaling $951 million USD. This includes rehabilitating the Water and Sewage System in Havana, Cuba, where the SFD has allocated $35 million to enhance public infrastructure. Another significant initiative is the rebuilding of St. Jude Hospital in Saint Lucia, supported by $75 million funding, which will contribute to providing high-quality health services to citizens in a modern and sophisticated facility and providing sufficient medical supplies and equipment to support the effective operation of the hospital.
In Eastern Europe, the SFD has contributed to 14 projects with a total investment of $303 million. A key initiative is the construction of the Tirana-Elbasan-Chokos-Chalf-Ploce Road, where the SFD provided $73.8 million to rebuild essential roads and bridges, thereby boosting regional economic activities.
During the celebration, esteemed speakers shared insights on the SFD’s pivotal role in global development, and in championing critical partnerships and collective action and response. Keynote speakers included:
- HRH Prince Turki bin Faisal Al Saud, Founder and Trustee of the King Faisal Foundation
- H.E. Ahmed bin Aqeel Al-Khateeb, Chairman of the Board of Directors of the SFD
- H.E. Akinwumi Adesina, President of the African Development Bank Group
- H.E. Muhammad Al Jasser, Chairman of the Islamic Development Bank
These global development leaders emphasized the SFD’s commitment to fostering sustainable growth in countries and communities with the most pressing developmental needs.
The gala was attended by more than 500 people, including ministers, heads of regional and international organizations, ambassadors, representatives of the United and other distinguished guests.
As the SFD looks to the future, it reaffirms its mission and pledge to drive international development efforts, on behalf of the Kingdom of Saudi Arabia, and to contribute to global stability, social progress, and economic prosperity for future generations.
Note to editors
- For additional information, please reach out to us at media@sfd.gov.sa
- Access the media kit, including collateral from the anniversary, via the following link: media kit
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240902588222/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
